Elite Pharmaceuticals, Inc.
ELTPOTCHealthcare● Active
$0.37
+$0.00(+0.48%)
Market Cap$400513437
P/E Ratio—
52W High$0.82
52W Low$0.33
Elite Pharmaceuticals, Inc. (ELTP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ELTP · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $84.04M | $56.63M | $34.16M | $32.26M | $25.38M |
| Cost of Revenue | $43.96M | $30.27M | $17.56M | $17.47M | $13.51M |
| Gross Profit | $40.09M | $26.36M | $16.59M | $14.80M | $11.87M |
| Gross Margin %(computed) | 47.70% | 46.55% | 48.58% | 45.86% | 46.76% |
| Operating Expenses | |||||
| R&D Expenses | $7.96M | $6.88M | $6.20M | $4.05M | $5.11M |
| G&A Expenses | $9.23M | $6.96M | $5.12M | $4.48M | $3.34M |
| Total Operating Expenses | $20.49M | $15.57M | $12.92M | $9.72M | $9.76M |
| Operating Income | $19.60M | $10.79M | $2025.11M | $5.07M | $2.10M |
| Operating Margin %(computed) | 23.32% | 19.05% | — | 15.72% | 8.29% |
| Interest Income | $0.02M | $0.02M | $0.01M | $0.00M | $0.00M |
| Interest Expense | $0.77M | $0.59M | $1.11M | $0.19M | $0.26M |
| Income Before Tax | ($0.05M) | $0.46M | $3.99M | $7.16M | $4.14M |
| Income Tax Expense | $4.26M | ($19.65M) | ($424.03M) | ($1.74M) | ($0.94M) |
| Net Income | ($4.31M) | $20.11M | $4.41M | $8.90M | $5.09M |
| Net Margin %(computed) | -5.13% | 35.51% | 12.91% | 27.58% | 20.05% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.00 | $0.02 | $4.35 | $0.01 | $0.01 |
| Wtd Avg Shares | 1068.29M | 1015.44M | 1012.91M | 1010.61M | 943.00M |
| EBITDA | $2.84M | $2.52M | $6.43M | $6.49M | $3.63M |
| EBITDA Margin %(computed) | 3.38% | 4.46% | 18.82% | 20.12% | 14.30% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Elite Pharmaceuticals, Inc. data
About Elite Pharmaceuticals, Inc. (ELTP) Income Statement
Elite Pharmaceuticals, Inc. (ELTP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ELTP reported revenue of $0.08B, gross profit of $0.04B (gross margin 47.70%), and net income of ($0.00B) — a net profit margin of -5.13%.
Frequently asked questions
ELTP · 4 questionsElite Pharmaceuticals, Inc. (ELTP) reported revenue of $0.08B for 2025, up 48.4% year-over-year.
ELTP revenueELTP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09